INmune Bio Inc. found using ticker (INMB) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 26 and 15 calculating the mean target price we have 20. Now with the previous closing price of 21.77 this is indicating there is a potential downside of -8.1%. The 50 day MA is 12.26 while the 200 day moving average is 10.22. The company has a market cap of $292m. Find out more information at: http://www.inmunebio.com
INmune Bio, a clinical-stage immunotherapy company, focuses on reprogramming the patient’s innate immune system to treat cancer Alzheimer’s disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer’s disease; and LivNate to treat patients with non-alcoholic steatohepatitis. The company has license agreements with Xencor; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio was founded in 2015 and is headquartered in La Jolla, California.